Evaluation of tumor-infiltrating lymphocytes using routine H&E slides predicts patient survival in resected non-small cell lung cancer

被引:51
|
作者
Rakaee, Mehrdad [1 ]
Kilvaer, Thomas K. [2 ,3 ]
Dalen, Stig Manfred [4 ]
Richardsen, Elin [1 ,4 ]
Paulsen, Erna-Elise [2 ,3 ]
Hald, Sigurd M. [3 ]
Al-Saad, Samer [1 ,4 ]
Andersen, Sigve [2 ,3 ]
Donnem, Tom [2 ,3 ]
Bremnes, Roy M. [2 ,3 ]
Busund, Lill-Tove [1 ,4 ]
机构
[1] UiT Arctic Univ Norway, Dept Med Biol, N-9019 Tromso, Norway
[2] Univ Hosp North Norway, Dept Oncol, N-9019 Tromso, Norway
[3] UiT Arctic Univ Norway, Dept Clin Med, N-9019 Tromso, Norway
[4] Univ Hosp North Norway, Dept Clin Pathol, N-9019 Tromso, Norway
关键词
TILs; Tumor-infiltrating lymphocytes; NSCLC; Prognosis; Lung cancer; Immunoscore; STAGE; RECOMMENDATIONS; CLASSIFICATION; IMMUNOSCORE; DENSITY; RECURRENCE; PROGNOSIS; MARKER; IMPACT; TILS;
D O I
10.1016/j.humpath.2018.05.017
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The presence of tumor-infiltrating lymphocytes (TILs) positively impacts the outcome of non- small cell lung cancer (NSCLC) patients. Most previous studies have assessed TILs using different immunohistochemical assays. The purpose of this study was to develop and validate a histopathological scoring model for the assessment of TILs in whole-tissue hematoxylin and eosin (H&E)-stained section slides of NSCLC patients and to evaluate the model in an immunoscore setting. Therefore, TIL was evaluated manually on H&E slides from 537 surgical specimens of primary resected stage I-III NSCLC patients. Using stromal TIL score as a stepwise discrete variable, increasing survival was seen with rising TIL level: disease-specific survival (DSS; P = .008), overall survival (P = .036) and disease-free survival (P = .006). Subgroup analysis revealed that high stromal TILs level was associated with superior DSS (P = .047) in patients with squamous cell carcinoma, but not in patients with adenocarcinoma. Multivariable analysis confirmed that high TIL levels independently predict improved prognosis for all endpoints in the overall cohort. In conclusion, high stromal TIL level is an independent favorable prognostic factor in stage NSCLC patients. The comprehensive histological evaluation conducted in this study may be helpful in streamlining TIL quantification for routine clinical use in a future NSCLC immunoscore setting. (C) 2018 Elsevier Inc. All rights reserved.
引用
收藏
页码:188 / 198
页数:11
相关论文
共 50 条
  • [21] Number of metastatic lymph nodes in resected non-small cell lung cancer predicts patient survival
    Lee, Jin Gu
    Lee, Chang Young
    Park, In Kyu
    Kim, Dae Joon
    Park, Seong Yong
    Kim, Kil Dong
    Chung, Kyung Young
    ANNALS OF THORACIC SURGERY, 2008, 85 (01): : 211 - 215
  • [22] Prognostic impact of LILRB4 expression on tumor-infiltrating cells in resected non-small cell lung cancer
    Kumata, Sakiko
    Notsuda, Hirotsugu
    Su, Mei-Tzu
    Saito-Koyama, Ryoko
    Tanaka, Ryota
    Suzuki, Yuyo
    Funahashi, Junichi
    Endo, Shota
    Yokota, Isao
    Takai, Toshiyuki
    Okada, Yoshinori
    THORACIC CANCER, 2023, 14 (21) : 2057 - 2068
  • [23] Interaction of Tumor Infiltrating Lymphocytes and Cancer Nuclei Predicts Response to Nivolumab in Non-Small Cell Lung Cancer (NSCLC)
    Wang, X.
    Barrera, C.
    Lu, C.
    Velcheti, V.
    Madabhushi, A.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S393 - S393
  • [24] Classifying Non-Small Cell Lung Cancer by Status of Programmed Cell Death Ligand 1 and Tumor-Infiltrating Lymphocytes on Tumor Cells
    Cui, Shaohua
    Dong, Lili
    Qian, Jialin
    Ye, Lin
    Jiang, Liyan
    JOURNAL OF CANCER, 2018, 9 (01): : 129 - 134
  • [25] Morphological tumor-infiltrating lymphocytes evaluation in biopsies from patients with non-small cell lung carcinoma: useful or useless?
    Debiche, Soumaya
    Cherif, Hela
    Ben Rjab, Sarra
    Ben Soltana, Feriel
    Daoud, Sirine
    Triki, Mariem
    Mokaddem, Salma
    Yangui, Ferdaous
    Charfi, Mohamed Ridha
    Debiche, Soumaya
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64
  • [26] Expansion of tumor-infiltrating lymphocytes in non-small cell lung cancer: Clinical potential and efficacy in EGFR mutation subsets
    Lee, Hyun
    Lee, Miseon
    Lim, Chae Lyul
    Park, Hye Seon
    Song, In Hye
    Jeong, Byung-Kwan
    Kim, Dong Kwan
    Kim, Yong-Hee
    Choi, Sehoon
    Lee, Geun Dong
    Lee, Sae Byul
    Jung, Sungwook
    Kim, Sung-Bae
    Gong, Gyungyub
    Yoo, Changhoon
    Kim, Joo Young
    Lee, Hee Jin
    CLINICAL IMMUNOLOGY, 2024, 265
  • [27] Phenotypic analysis of tumor-infiltrating lymphocytes from non-small cell lung cancer and their potential application for adoptive cell therapy
    Ma, Yipeng
    Ou, Jiayu
    Lin, Tong
    Chen, Lei
    Wang, Juntao
    Qiao, Dongjuan
    Lai, Shuoyan
    Duan, Chaojun
    Cheng, Yuanda
    Chang, Ruimin
    Zhang, Chunfang
    Wang, Mingjun
    IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY, 2020, 42 (04) : 319 - 329
  • [28] Prognostic and predictive value of tumor-infiltrating lymphocytes for clinical therapeutic research in patients with non-small cell lung cancer
    Zeng, Dong-Qiang
    Yu, Yun-Fang
    Ou, Qi-Yun
    Li, Xiao-Yin
    Zhong, Ru-Zhi
    Xie, Chuan-Miao
    Hu, Qiu-Gen
    ONCOTARGET, 2016, 7 (12) : 13765 - 13781
  • [29] Phenotypic and Functional Profiling of Tumor-Infiltrating Lymphocytes (TIL) in Early Stage Non-Small Cell Lung Cancer (NSCLC)
    Federico, Lorenzo
    Haymaker, Cara
    Forget, Marie-Andree
    Vence, Luis
    Team, Icon
    Sharma, Padmanee
    Allison, James
    Fang, Bingliang
    Zhang, Jianjun
    Wagner, Heidi
    Bogatenkova, Elena
    Wistuba, Ignacio
    Sepesi, Boris
    Heymach, John
    Gibbons, Don Lynn
    Bernatchez, Chantale
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S630 - S631
  • [30] Prognostic implications of tumor-infiltrating lymphocytes in non-small cell lung cancer: a systematic review and meta-analysis
    Yan, Qin
    Li, Shuai
    He, Lang
    Chen, Nianyong
    FRONTIERS IN IMMUNOLOGY, 2024, 15